Discussion about this post

User's avatar
Alainjasaf's avatar

Dr. Mandrola, I agree with your bottom line: standard duration remains the default. But I think the strongest case against the authors' conclusion is in the protocol, not in the main paper.

In protocol version 1 (2018), the primary endpoint was a composite of death, embolism, and bacteremia with the same organism. The November 2023 amendment did three things after a (blinded) interim analysis: it made "days alive without antibiotics" the primary endpoint, removed relapse from the safety composite, and widened the noninferiority margin from 5 to 7.5 percentage points. In the sensitivity analysis that puts relapse back in, the upper CI bound is 5.54. That would fail the original 5-point margin.

Second, the benefits that justify a noninferiority design never materialized. Total adverse events were 150 vs. 151, antibiotic-related events 54 vs. 55, and IV-line complications 48 vs. 44. Quality of life was dropped from the endpoints, and costs and length of stay were not reported.

One caution in the other direction: "3x, up to 10x" is relative framing built on 17 events. In absolute terms it is 3.5 percentage points, an NNH of about 29, with a fragility index of 1. The signal is real and well-timed (median 28 days to relapse), but imprecise.

So the conclusion holds, and I think it is stronger than "clearly worse": more relapse, and no measured benefit to pay for it.

Paul Sax's avatar

Agree. And most of the ID doctors with whom I've discussed these results are on the same page as we are. A significantly higher relapse rates is too concerning a signal to change standard of care.

23 more comments...

Ready for more?